Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€37.21

€37.21

-0.560%
-0.21
-0.560%
€40.13
 
19:38 / Tradegate WKN: 936718 / Symbol: EXEL / Name: Exelixis / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Financial data and news for Exelixis

sharewise wants to provide you with the best news and tools for Exelixis, so we directly link to the best financial data sources.

News

Exelixis Stock: Executives Sell as Shares Near Peak
Exelixis Stock: Executives Sell as Shares Near Peak

Exelixis is experiencing significant insider selling activity while its stock trades near its 52-week high of €37.64. Three high-ranking executives recently reduced their holdings in substantial

2 Top Stocks to Buy With Less Than $100: https://g.foolcdn.com/editorial/images/819375/patient-talking-with-a-physician.jpg
2 Top Stocks to Buy With Less Than $100

When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that

Why Exelixis Stock Is Skyrocketing Today: https://g.foolcdn.com/editorial/images/818283/rocket-drawn-with-ben-franklin-from-100-bill.jpg
Why Exelixis Stock Is Skyrocketing Today

Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after the drugmaker announced its 2025 first-quarter results Tuesday evening.

Why Exelixis Stock Trounced the Market on Thursday
Why Exelixis Stock Trounced the Market on Thursday

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to

Exelixis (EXEL) Q4 2024 Earnings Call Transcript
Exelixis (EXEL) Q4 2024 Earnings Call Transcript

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q4 2024 Earnings CallFeb 11, 2025, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Exelixis Posts 63.7% Profit Surge
Exelixis Posts 63.7% Profit Surge

Exelixis (NASDAQ:EXEL), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and